Menu
Fechar
hrs4r
 I want to donate

The Haematology research group at the IDIBGI started in 2007 as an extension of the haematology service at ICO Girona. The group is dedicated to clinical and translational studies in relation to diagnostic, prognostic, and therapeutic processes in hemopathies, the group is made up of haematologists, nurses, biologists and technicians.

Main lines of research
  • Study genetic variants involved in the immune response as survival predictors and graft disease against the host after allogenic transplantation of hematopoietic progenitors.
  • Study biological and pharmacogenomic aspects associated with response to the treatment of acute myeloblastic leukaemia
  • Analysis of genetic polymorphisms as predictors of multiple myeloma progression.
  • Study of genetic polymorphisms involved in evolution and the response to treatment of chronic lymphatic leukaemia.
  • Study of cell populations using flow cytometry for the characterization of hemopathies and detection of residual disease.
Strategic objectives
  • To investigate biological, clinical, and epidemiological aspects of haematological diseases
  • To carry out translational research projects focused on finding prognostic factors or treatment response predictors
  • To carry out clinical research, promoting participation in clinical trials for haematological diseases and participating in national or international cooperative groups.
Publications
Gonzalez-Gil C, Morgades M, Lopes T, Fuster-Tormo F, Montesinos P, Barba P, Diaz-Beya M, Hermosin L, Maluquer C, Gonzalez-Campos J, Bernal T, Arriaga MS, Zamora L, Pratcorona M, Martino R, Larrayoz MJ, Artola T, Torrent A, Vall-Llovera F, Tormo M, Gil C, Novo A, Martinez-Sanchez P, Ribera J, Queipo MP, Gonzalez-Martinez T, Cabrero M, Cladera A, Cervera J, Orfao A, Ribera JM, Genesca E

Contribution of copy number to improve risk stratification of adult T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials.

Haematologica, 2025, 110, 206-211 dx.doi.org/10.3324/haematol.2024.285416
Castaño-Díez S, López-Guerra M, Zugasti I, Calvo X, Schulz FI, Avendaño A, Mora E, Falantes-González JF, Azaceta G, Ibañez M, Chen-Liang TH, Notario Mc Donnell C, Amer-Salas N, Palomo L, Pomares H, Vila J, Bernal Del Castillo T, Jiménez-Vicente C, Esteban D, Guijarro F, Álamo Moreno JR, Cortés-Bullich A, Torrecillas-Mayayo V, Triguero A, Mont-de Torres L, Carcelero E, Cardús A, Germing U, Betz B, Rozman M, Arenillas L, Zamora L, Díez-Campelo M, Xicoy B, Esteve J, Díaz-Beyá M

AML typical mutations (CEBPA, FLT3, and NPM1) identify a high-risk CMML independent of CPSS-Mol classification.

Blood Advances, 2025, 9, 39-53 dx.doi.org/10.1182/bloodadvances.2024013648
Ramírez MJ, Pujol R, Minguillón J, Bogliolo M, Persico I, Cavero D, de la Cal A, Río P, Navarro S, Casado JA, Bailador A, de la Fuente AS, de Heredia ML, Almazán F, Antelo ML, Argilés B, Badell I, Baragaño M, Beléndez C, Bermúdez M, Bernués M, Buedo MI, Carrasco E, Català A, Costa D, Cuesta I, Fernandez-Delgado R, Fernández-Teijeiro A, Figuera Á, García M, Gondra A, González M, Muñiz SG, Hernández-Rodríguez I, Ibañez F, Kelleher NJ, Lendínez F, López M, López-Almaraz R, Marchante I, Mendoza C, Nieto J, Ojeda E, Payán-Pernía S, Peláez I, de Soto IP, Portugal R, Ramos-Arroyo MA, Regueiro A, Rodríguez A, Rosell J, Saez R, Sánchez J, Sánchez M, Senent M, Tapia M, Trujillo-Quintero JP, Vagace JM, Verdú-Amorós J, Verdugo V, Vidales I, Villarreal J, Díaz-de-Heredia C, Sevilla J, Bueren JA, Surrallés J

Prognostic significance of mutation type and chromosome fragility in Fanconi anemia.

AMERICAN JOURNAL OF HEMATOLOGY, 2025, 100, 272-284 dx.doi.org/10.1002/ajh.27520
Oñate G, Garrido A, Arnan M, Pomares H, Alonso E, Tormo M, Diaz-Beya M, Vives S, Zamora L, Sampol A, Coll R, Salamero O, Cervera M, Garcia A, Vall-Llovera F, Garcia-Avila S, Bargay J, Ortin X, Iranzo E, Guijarro F, Pratcorona M, Nomdedeu JF, Esteve J, Sierra J

Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group.

BLOOD CANCER JOURNAL, 2025, 15, 4-4 dx.doi.org/10.1038/s41408-024-01205-5
Garcia-Guiñon A, Charry PA, Jimenez M, Sarra J, Delgado I, Segura de la Torre L, Santaliestra M, Garcia-Pintos M, Gonzalez Y, Senin A, Motlló C, Abella E, Cabezudo E, Granell M, Sancho E, Herranz MJ, Seres Y, Gironella M, Soler JA, Marti-Tutusaus JM, Ben Azaiz R, Fernandez de Larrea C

Real-world evidence of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Scheme in patients with relapsed / refractory multiple myeloma.

ANNALS OF HEMATOLOGY, 2025 dx.doi.org/10.1007/s00277-025-06240-1
Pomares AA, Merino LR, González S, Morata J, Tonda R, Arribas P, Revert J, Carrillo E, Grande C, Roncero JM, de Oteyza JP, Nicolás C, Gutierrez N, Abrisqueta P, Gutiérrez A, Ramírez-Páyer Á, Garcia-Sancho AM, González-Barca E, Montes-Moreno S

Genetic subtyping by Whole Exome Sequencing across Diffuse Large B Cell Lymphoma and Plasmablastic Lymphoma.

Plos One, 2025, 20 dx.doi.org/10.1371/journal.pone.0318689
Carbo-Meix A, Guijarro F, Wang L, Grau M, Royo R, Frigola G, Playa-Albinyana H, Buhler MM, Clot G, Duran-Ferrer M, Lu J, Granada I, Baptista MJ, Navarro JT, Espinet B, Puiggros A, Tapia G, Bandiera L, De Canal G, Bonoldi E, Climent F, Ribera-Cortada I, Fernandez-Caballero M, De la Banda E, Do Nascimento J, Pineda A, Vela D, Rozman M, Aymerich M, Syrykh C, Brousset P, Perera M, Yanez L, Ortin JX, Tuset E, Zenz T, Cook JR, Swerdlow SH, Martin-Subero JI, Colomer D, Matutes E, Bea S, Costa D, Nadeu F, Campo E

BCL3 rearrangements in B-cell lymphoid neoplasms occur in two breakpoint clusters associated with different diseases

Haematologica, 2024, 109, 493-508 dx.doi.org/10.3324/haematol.2023.283209
Ribera JM, Morgades M, Garcia-Calduch O, Sirvent M, Buendia B, Cervera M, Luzardo H, Hernandez-Rivas JM, Sitges M, Garcia-Cadenas I, Abrisqueta P, Montesinos P, Bastos-Oreiro M, De Llano MQ, Bravo P, Torrent A, Herrera P, Garcia-Guinon A, Vall-Llovera F, Serrano J, Terol MJ, Bergua JM, Garcia-Noblejas A, Barrenetxea C, Llorente L, Garcia-Belmonte D, Gimeno E, Cladera A, Mercadal S, Sancho JM

Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial.

Haematologica, 2024, 109, 543-552 dx.doi.org/10.3324/haematol.2023.283342
Lakhwani S, Rosiñol L, Puig N, Pico-Picos MA, Medina-González L, Martínez-López J, Paiva B, Cedena MT, Oriol A, Ríos-Tamayo R, Blanchard MJ, Jarque I, Bargay J, Moraleda JM, Carrillo-Cruz E, Sureda A, Krsnik I, González E, Casado LF, Martí JM, Encinas C, De Arriba F, Palomera L, Sampol A, González-Montes Y, Motlló C, De La Cruz J, Alonso R, Mateos MV, Bladé J, Lahuerta JJ, San-Miguel J, Hernández MT

Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection.

Haematologica, 2024, 109, 1909-1917 dx.doi.org/10.3324/haematol.2023.284154
Hernández-Sánchez A, Villaverde-Ramiro Á, Arellano-Rodrigo E, Garrote M, Martín I, Mosquera-Orgueira A, Gómez-Casares MT, Ferrer-Marín F, Such E, Velez P, Ayala R, Angona A, de Las Heras N, Magro E, Mata-Vázquez MI, Fox ML, de Villambrosía SG, Ramírez MJ, García A, García-Gutiérrez V, Cáceres A, Durán MA, Senín A, Raya JM, González JA, Cuevas B, Xicoy B, Pérez-Encinas M, Bellosillo B, Álvarez-Larrán A, Hernández-Rivas JM, Hernández-Boluda JC

The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis

AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99, 755-758 dx.doi.org/10.1002/ajh.27203
Competitive projects
Haematology

Genotipo de las moléculas inhibidoras de respuesta inmune: más allá del trasplante alogénico. Banco nacional de ADN de pacientes tratados con terapia CAR-T.

Codi oficial: PI20/01353 Start date:01/01/2021 Data fi: 30/06/2025 Investigador/a principal: DAVID GALLARDO GIRALT Organisme finançador: INSTITUTO DE SALUD CARLOS III
Haematology

Relevancia del genotipo de LAG3 y moléculas checkpoint en el trasplante alogénico de progenitores hematopyéticos.

Codi oficial: Projecte IJC - Dr. David Gallardo Start date:01/07/2021 Data fi: 30/06/2025 Investigador/a principal: DAVID GALLARDO GIRALT Organisme finançador: FUNDACIÓ INSTITUT DE RECERCA CONTRA LA LEUCÈMIA JOSEP CARRERAS
Haematology

Ajuts per donar suport a les activitats dels grups de recerca de Catalunya (SGR-Cat 2021) - Hematologia

Codi oficial: 2021 SGR 01511 Start date:01/01/2022 Data fi: 30/06/2025 Investigador/a principal: DAVID GALLARDO GIRALT Organisme finançador: AGÈNCIA DE GESTIÓ UNIVERSITARIS I RECERCA
Job offers

Team

If you are a researcher and you are interested in collaborating with any of our research groups, please fill in this form.
I am interested in
If you are a student or you want to do an internship with any of our research groups, please fill in this form.
I am interested in

About IDIBGI!

 menu